Reuters logo
a month ago
BRIEF-Aptevo Therapeutics and Alligator Bioscience announce plans to co-develop novel bispecific antibody for tumor-directed immunotherapy
July 20, 2017 / 9:26 PM / a month ago

BRIEF-Aptevo Therapeutics and Alligator Bioscience announce plans to co-develop novel bispecific antibody for tumor-directed immunotherapy

July 20 (Reuters) - Aptevo Therapeutics Inc

* Aptevo Therapeutics and Alligator Bioscience announce plans to co-develop novel bispecific antibody for tumor-directed immunotherapy

* Aptevo Therapeutics Inc - Initiation of cell line development for manufacturing of clinical material is expected to begin shortly

* Aptevo Therapeutics - At time of phase 2 clinical development parties May opt to out-license candidate/continue development separately/ in partnership

* Aptevo Therapeutics - Agreement provides an option for companies to develop a second bispecific antibody candidate ,which would also be jointly owned and funded

* Aptevo Therapeutics - Parties will jointly own, share equally in development costs of advancing alg.APV-527 through to phase 2 clinical development end Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below